Date | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities | Dividends Paid | Capital Expenditure |
---|
CEO | Ms. Terrie J. Curran |
IPO Date | Oct. 25, 2019 |
Location | United States |
Headquarters | 100 Campus Drive |
Employees | 452 |
Sector | Health Care |
Industries |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Past 5 years
USD 1.42
USD 20.66
USD 4.18
USD 1.57
USD 11.25
USD 13.01
USD 2.06
USD 30.75
USD 114.32
USD 3.46
StockViz Staff
January 30, 2025
Any question? Send us an email